MedTrace Logo

Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis

NCT02643823 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-05-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of human umbilical cord mesenchymal stem cell(hUC-MSC) for Rheumatoid Arthritis.

Conditions

Interventions

BIOLOGICAL

hUC-MSC + DMARDs

Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.

DRUG

DMARDs

Patients will be treated by conventional drugs (DMARDs) for alleviating disease.

Sponsors & Collaborators

  • Futian People's Hospital

    collaborator OTHER

  • Shenzhen Hornetcorn Bio-technology Company, LTD

    lead INDUSTRY

Principal Investigators

  • Zhong Z Ye, Professor · Futian People's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-01-31
Completion
2017-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02643823 on ClinicalTrials.gov